Prognostic Factors and Outcome in Askin-Rosai Tumor: A Review of 104 Patients

Journal Article · Sat Jan 01 04:00:00 EST 2011 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2009.10.039· OSTI ID:21491555

Laskar, Siddhartha ^[1]; Nair, Chandrika ^[2]; Mallik, Suman; Bahl, Gaurav ^[1]; Pai, Suresh ^[2]; Shet, Tanuja ^[3]; Gupta, Tejpal ^[1]; Arora, Brijesh; Bakshi, Ashish ^[2]; Pramesh, C S; Mistry, Rajesh; Qureshi, Sajid ^[4]; Medhi, Seema ^[5]; Jambhekar, Nirmala ^[3]; Kurkure, Purna; Banavali, Shripad ^[2]; Muckaden, Mary Ann ^[1]

---

1. Department of Radiation Oncology, Tata Memorial Hospital, Mumbai (India)
2. Department of Medical Oncology, Tata Memorial Hospital, Mumbai (India)
3. Department of Pathology, Tata Memorial Hospital, Mumbai (India)
4. Department of Surgical Oncology, Tata Memorial Hospital, Mumbai (India)
5. Department of Radiology, Tata Memorial Hospital, Mumbai (India)

Purpose: To evaluate the prognostic factors and treatment outcome of patients with Askin-Rosai tumor of the chest wall treated at a single institution. Methods and Materials: Treatment comprised multiagent chemotherapy and local therapy, which was either in the form of surgery alone, radical external-beam radiotherapy (EBRT) alone, or a combination of surgery and EBRT. Thirty-two patients (40%) were treated with all three modalities, 21 (27%) received chemotherapy and radical EBRT, and 19 (24%) underwent chemotherapy followed by surgery only. Results: One hundred four consecutive patients aged 3-60 years were treated at the Tata Memorial Hospital from January 1995 to October 2003. Most (70%) were male (male/female ratio, 2.3:1). Asymptomatic swelling (43%) was the most common presenting symptom, and 25% of patients presented with distant metastasis. After a median follow-up of 28 months, local control, disease-free survival, and overall survival rates were 67%, 36%, and 45%, respectively. Median time to relapse was 25 months, and the median survival was 76 months. Multivariate analysis revealed age {>=}18 years, poor response to induction chemotherapy, and presence of pleural effusion as indicators of inferior survival. Fifty-six percent of patients with metastatic disease at presentation died within 1 month of diagnosis, with 6-month and 5-year actuarial survival of 14% and 4%, respectively. Conclusion: Primary tumor size, pleural effusion, response to chemotherapy, and optimal radiotherapy were important prognostic factors influencing outcome. The combination of neoadjuvant chemotherapy, surgery, and radiotherapy resulted in optimal outcome.

• OSTI ID: 21491555
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 1 Vol. 79; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BODY
CHEMOTHERAPY
CHEST
DEFORMATION
DISEASES
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
RADIOLOGY
RADIOTHERAPY
SURGERY
SWELLING
SYMPTOMS
THERAPY
WALLS